Contrast media developer CMC Contrast of Stockholm, Sweden, said that it has begun phase III studies at Karolinska University Hospital in Huddinge, Sweden, on a new contrast medium, CMC 001, for MR imaging of liver tumors.
CMC 001 is orally administered and is designed for screening liver tumors and metastases, and for imaging of the biliary tract, the company said. The phase I study was performed at Gentofte Hospital outside Copenhagen, Denmark, and the phase II study was conducted at the University Hospital in Nijmegen in the Netherlands.
By AuntMinnie.com staff writers
October 6, 2005
Copyright © 2005 AuntMinnie.com
